Use of the Insulin Pump in Cystic Fibrosis Patients With Impaired Glucose Tolerance or CFRD and in Type 1 Diabetes Patients.

Withdrawn before enrolling · Not applicable

Conditions studied: Cystic Fibrosis Related Diabetes

In brief

We hypothesize use of the insulin pump will improve body weight, lean body mass, whole body protein turnover, hepatic glucose production (HGP), and blood sugar control in CF patients with impaired glucose tolerance or patients with CF related diabetes (CFRD). We further hypothesize that HGP is also elevated in children/adolescents with type 1 diabetes and that the insulin pump will result in decreased HGP.

Key facts

Study ID

NCT00287456

Run by

University of Texas Southwestern Medical Center

People needed

0

Starts

2006-02-02

Expected to finish

2006-02-02

Last updated by the study team

2019-01-10

Who can join

Age: 12 and older, up to 32. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Cystic fibrosis patients aged 12-32 years
• Impaired glucose tolerance or CFRD defined as fasting blood glucose (FBG) and post-prandial blood glucose (pp) equal to: FBG <126 and pp 151-200, or FBG <126 and pp >200, or FBG >126 and pp >200.
• Type 1 diabetes control patients aged 12-32 years.

You may not qualify if…

• Colonization with Burkholderia cepacia
• currently on corticosteroid medication
• pregnant
• medically unstable
• Unable to understand the insulin pump directions

Where it is running

• Children's Medical Center of Dallas — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.